Haploidentical Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Case Report First Experience
DOI:
https://doi.org/10.3889/oamjms.2021.7542Keywords:
Haploidenthical transplantation, Myelodysplastic syndrome, SurvivalAbstract
BACKGROUND: Allogeneic stem cell transplantation (ASCT) is a potentially curative therapeutic approach in patients with intermediate and high-risk myelodysplastic syndrome (MDS). If a family sibling or unrelated donor is not available mismatched donors are viable option for young patients with no comorbidities. The aim of this case presentation was to evaluate our first experience with haploidentical transplantation for this indication.
CASE PRESENTATION: We present a case of 50 years male patient with myelodysplastic syndrome (MDS) diagnosed at University Clinic for hematology, Skopje, North Macedonia. Patient was scored in IPSS -R as high risk patient. He was referred for HLA DNA typing of family siblings and since he didn’t have identical sibling and unrelated donor, he was referred to continue treatment with haploidentical stem cell transplantation. He received Flu Bu conditioning and PTCY, cyclosporine and MMF for GVHD prophylaxis. Peripheral blood stem cells (PBSC) from his mismatched brother were infused in the amount of CD34=5.8x106/kg. He experienced prolonged engraftment, severe infective bacterial infections and CMV reactivation with clinical manifestation of CMV colitis. He was successfully treated with antiviral drug and completely resolved. His bone marrow analysis showed complete remission and chimerism evaluation revealed high donor engraftment. Patient is now +34 months post transplant in complete remission.
CONCLUSION: The use of a mismatched donor increases the risk of NRM, but there is also evidence to suggest that an haploidentical donor is a valid choice, as general outcome appears to be at least similar to MUD.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Duarte RF, Myriam L, Peter B, Grzegorz W, Chiara B, Ch C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525-52. https://doi.org/10.1038/s41409-019-0516-2 PMid:30953028 DOI: https://doi.org/10.1038/s41409-019-0516-2
Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, et al. Haploidentical transplant in patients with myelodysplastic syndrome. Blood Adv. 2017;1(22):1876-83. https://doi.org/10.1182/bloodadvances.2017007146 PMid:29296834 DOI: https://doi.org/10.1182/bloodadvances.2017007146
Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European society for blood and marrow transplantation (EBMT) Consensus guidelines for the detection and treatment of donorspecific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(5):521-34. https://doi.org/10.1038/s41409-017-0062-8 PMid:29335625 DOI: https://doi.org/10.1038/s41409-017-0062-8
Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in china-recommendations from the Chinese society of hematology. J Hematol Oncol. 2018;11(1):33. https://doi.org/10.1186/s13045-018-0564-x PMid:29495966 DOI: https://doi.org/10.1186/s13045-018-0564-x
Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: An update. Bone Marrow Transplant. 2015;50 Suppl 2:S37-9. https://doi.org/10.1038/bmt.2015.93 PMid:26039205 DOI: https://doi.org/10.1038/bmt.2015.93
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65. https://doi.org/10.1182/blood-2012-03-420489 PMid:22740453 DOI: https://doi.org/10.1182/blood-2012-03-420489
Ades L, Itzykson PF, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239-52. https://doi.org/10.1016/S0140-6736(13)61901-7 PMid:24656536 DOI: https://doi.org/10.1016/S0140-6736(13)61901-7
Villar S, Robin M. Allogeneic stem cell transplantation for MDS. Hematology. 2021;2:545-55. https://doi.org/10.3390/hemato2030034 DOI: https://doi.org/10.3390/hemato2030034
Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260-72. https://doi.org/10.1016/S1473-3099(19)30107-0 PMid:31153807 DOI: https://doi.org/10.1016/S1473-3099(19)30107-0
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Aleksandra Pivkova-Veljanovska, Irina Panovska-Stavridis, Lazar Chadievski, Sanja Trajkova, Marija Popova-Labachevska, Tara Mojsovska, Simona Stojanoska, Nevenka Ridova, Svetlana Krstevska-Balkanov, Zlate Stojanoski, Dejan Spasovski, Radica Grubovic-Rastvorceva, Borce Georgievski (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
